Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 176 golcadomide for relapsed or refractory CNS large B-cell lymphoma
2024-517051-12-00Phase 2Authorised
- Sponsor
- HOVON
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of golcadomide in Diffuse Large B-Cell Primary Central Nervous System Lymphoma and secondary central nervous system lymphoma (SCNSL) (2 cohorts), sponsored by HOVON. Primary endpoint: Best overall response. Planned start Jun 2025; status: authorised.
02
Drugs
golcadomide
03
Conditions
Diffuse Large B-Cell Primary Central Nervous System Lymphomasecondary central nervous system lymphoma (SCNSL)
Beyond the preview
Go deeper on 2024-517051-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517051-12-00.